Dan Paterson - 30 Sep 2026 Form 4 Insider Report for Verastem, Inc. (VSTM)

Reporting relationship: President and CEO, Director
Issuer ticker: VSTM
Reported as of: 30 Sep 2026
Net transaction value: -$352,968
SEC form: 4
Accepted by SEC: 02 Oct 2026, 17:15:49 UTC
Prior SEC filing: 05 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel Calkins, Attorney in Fact

Key filing fact

Dan Paterson filed Form 4 for Verastem, Inc. (VSTM) on 02 Oct 2026.

Key facts

This page summarizes Dan Paterson's Form 4 filing for Verastem, Inc. (VSTM).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 02 Oct 2026, 17:15.

Change

Previous filing in this sequence was filed on 05 Aug 2026.
Current net transaction value: -$352,968.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001563202 Primary reporting owner

Paterson Dan

Relationship: President and CEO, Director
Address: C/O VERASTEM, INC.,, 117 KENDRICK ST., SUITE 500, NEEDHAM
Signature: /s/ Daniel Calkins, Attorney in Fact
Signature date: 02 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VSTM transaction

Common Stock

Award

Transaction value
Shares: -106,893
Change %: -13%
Price: $0.000000^*
Shares after: 696,833
Date: 30 Sep 2026
Ownership: Direct
Footnotes: F1

VSTM transaction

Common Stock

Sale

Transaction value: $352,968
Shares: -44,121
Change %: -6.3%
Price: $8.00
Shares after: 652,712
Date: 01 Oct 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The reported securities were subject to a performance restricted stock units ("RSU") award that was granted on January 21, 2026. 106,893 RSUs vested on September 30, 2026, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria related to certain clinical development goals had been achieved.

Footnote F2

The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of RSUs.